# Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients

> **NCT05748925** · PHASE4 · COMPLETED · sponsor: **Mansoura University** · enrollment: 84 (actual)

## Conditions studied

- SLE
- Lupus Nephritis
- SGLT2 Inhibitors

## Interventions

- **DRUG:** dapagliflozin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05748925
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05748925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05748925, "Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05748925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*